The impact of GPX1 on the association of groundwater selenium and depression: a project FRONTIER study

Leigh A Johnson1*, Jack A Phillips2, Cortney Mauer3, Melissa Edwards3, Valerie Hobson Balldin4, James R Hall5, Robert Barber6, Tori L Conger7, Eric J Ho8 and Sid E O'Bryant9

Abstract

Background: Prior animal model and human-based studies have linked selenium concentrations to decreased risk for depression; however, this work has not focused on household groundwater levels or specific depressive symptoms. The current study evaluated the link between groundwater selenium levels and depression. We also sought to determine if a functional polymorphism in the glutathione peroxidase 1 (GPX1) gene impacted this link.

Methods: We used a cross-sectional design to analyze data from 585 participants (183 men and 402 women) from Project FRONTIER, a study of rural health in West Texas. Residential selenium concentrations were estimated using Geospatial Information System (GIS) analyses. Linear regression models were created using Geriatric Depression Scale (GDS-30) total and subfactor scores as outcome variables and selenium concentrations as predictor variables. Analyses were re-run after stratification of the sample on GPX1 Pro198Leu genotype (rs1050454).

Results: Selenium levels were significantly and negatively related to all GDS and subfactor scores accounting for up to 17% of the variance beyond covariates. Selenium was most strongly protective against depression among homozygous carriers of the C allele at the Pro198Leu polymorphism of the GPX1 gene. Analyses also point towards a gene-environmental interaction between selenium exposure and GPX1 polymorphism.

Conclusion: Our results support the link between groundwater selenium levels and decreased depression symptoms. These findings also highlight the need to consider the genetics of the glutathione peroxidase system when examining this relationship, as variation in the GPX1 gene is related to depression risk and significantly influences the protective impact of selenium, which is indicative of a gene-environment interaction.

Keywords: Aging, Depression, Environmental factors, Selenium, GPX1

Background

Depression is the most frequently occurring psychiatric disorder [1] with 1 in 10 adults reporting depression [2]. Depression has been shown to have a wide variety of adverse health outcomes including poorer physical and social functioning, and decreased quality of life [3-5] as well as an increase in morbidity and mortality [6-8]. Understanding the link between depression and environmental factors that may influence its occurrence, symptom presentation, and severity, may have a significant impact on our understanding of the biological mechanisms underlying depression and its treatment. Past research has shown relationships between depression and environmental factors, such as natural sour gas containing H2S [9] and pesticides [10]. Another naturally occurring substance that has been related to depression is selenium.

Past research has shown that selenoproteins are essential for numerous biological functions [11], many of which are thought to be related to depression. Depression is thought to be unpinned by multiple pathways, such as inflammation, oxidative and nitrosative stress, as well as a decrease in antioxidant levels [12-14]. Selenium, in the form of Selenoprotein P, protects the brain against oxidative damage.
selenium is an essential component in the glutathione peroxidase system, protects lipids in polyunsaturated membranes from oxidative degradation. Depression is often associated with lower levels of antioxidants, such as glutathione and GPx, glutathione peroxidase enzyme [16,17]. These findings suggest that selenium may be protective against depression, and selenium supplementation may have the potential to alleviate the symptoms of depression. However, research investigating the relationship between selenium and depression has yielded inconsistent findings. Low selenium concentrations have been related to increased incidence of many human diseases including depression [18–20]. Rayman et al. [21] failed to identify any benefit in mood or quality of life in a sample of elderly participants. Prenatal selenium supplementation has been linked to increased serum selenium levels as well as decreased risk for postpartum depression [22]. Pasco et al. [23] found that lower dietary selenium was related to a new diagnosis of major depression. Recently, Gao et al. [24] found that higher selenium were associated with lower GDS scores; however this effect was no longer significant when cognitive functioning was added to the model. This finding is interesting because it suggests that the link between selenium and depression may be impacted by individual factors, such as genetic variants that may impact the selenium levels in the body.

Selenium also plays a key role in proper functioning of the glutathione peroxidase system, which has been linked to depression. The glutathione peroxidase enzyme (GPx) is expressed in lower amounts among depressed patients, and GPx activity has been linked to depressed mood and autonomic symptoms [25]. Because functional variants have been identified within glutathione peroxidase genes, genetic variation within the glutathione peroxidase pathway is an important consideration when examining selenium-health status links. In particular, the Pro198Leu polymorphism of the glutathione peroxidase 1 (GPX1) gene (rs1050454) has received a great deal of attention recently in the literature [26]. This polymorphism contains a c.599C>T SNP, which is also referred to as rs1050450. The single nucleotide polymorphism (SNP) likely affects the activity of variant proteins [27]. The T allele of the rs1050450 GPX1 SNP has been associated with bladder, lung, and breast cancers, intracerebral hemorrhage [28], metabolic syndrome [29], and coronary artery disease [30]. It is functional in humans and impacts the response of GPX1 activity to selenium [31]. Genetic polymorphisms of the GPX1 gene have been shown to be related to tumor susceptibility [32], blood selenium levels associated with supplementation [33], and other health conditions. However, to date, we are aware of no studies that have examined the impact of GPX1 polymorphisms on the selenium-depression link.

The current study was designed to (a) study the link between groundwater selenium levels and depressive symptoms, (b) determine if the Pro198Leu GPX1 directly impact depression risk, and (c) determine if the Pro198Leu polymorphisms of the GPX1 gene impact these findings. It was hypothesized that higher groundwater selenium would be protective against depressive symptoms. No specific a priori hypotheses were made regarding the Pro198Leu polymorphism given that this is the first study to examine the role of this genetic variant in depression.

Methods

Participants and procedures

Data were analyzed from 585 participants (183 men and 402 women) from Project FRONTIER. Project FRONTIER is an ongoing study of factors impacting rural health that utilizes a community-based participatory research (CBPR) approach. The CBPR approach of partnering with community members and organizations is particularly useful when working with underserved communities, thus it is very well suited to rural health research and has been recommended by the National Institute on Environmental Health Sciences [34]. All participants signed written informed consents. Once participants have completed the consent process, s/he undergoes an interview (participant and informant), a standardized medical examination, clinical labs, and neuropsychological testing. Inclusion criteria are (a) age 40 and above and (b) residing in one of the counties included in Project FRONTIER. The counties currently included in project FRONTIER are Cochran County, Bailey County, and Parmer County, all of which are located on the Texas–New Mexico border. Participant recruitment is completed by community recruiters/assessors through multiple means including brochures/flyers, presentations and events, in-person and/or door-to-door solicitation, as well as snowball recruitment. Our prior work has shown that the research sample closely matches the demographics of the community at large [34]. Project FRONTIER is conducted under an IRB approved protocol. We have published findings utilizing this approach with Project FRONTIER elsewhere [35–37]. Project FRONTIER is conducted under the approval of Texas Tech Health Sciences Center IRB Board, L06-028. This archival analysis was conducted from a de-identified database under the approval of the University of North Texas Health Sciences Center IRB Review Board, protocol number 2012-071.

Measures

Geriatric depression scale (GDS-30)

The Geriatric Depression Scale was created specifically for screening depressive symptoms among older populations [38], and has been widely utilized in both clinical
and research settings. The GDS has demonstrated adequate internal consistency, test–retest reliability, and concurrent validity [39]. A recent factor analytic study [40] identified a four-factor solution underlying the scale. The Dysphoria factor contains 11 items primarily associated with a sad mood; the Meaninglessness factor consists of seven items that reflect an appraisal of the meaning (or lack thereof) in one’s life; the Apathy factor is made up of six items that reflect a lack of motivation or initiative; finally, the Cognitive Impairment factor consists of six items that reflect difficulty and concern with cognitive processes.

**Determination of GIS-selenium**

Geographic information system (GIS) analysis is a way of displaying and analyzing geographically referenced information that is frequently used to estimate environmental exposures [35,41-46]. We used the Environmental Systems Research Institute ArcGIS (release 9.2) program to plot a point for each of the selenium ground water measurements from the Texas Water Development Board (TWDB). Through inverse distance weighted (IDW) interpolation, the ArcGIS software built a three-dimensional surface map from a list of points. Each point’s influence was weighted based off its distance to that section of the map, which was generated using 12 well measurements from the TWDB within the immediate geographic vicinity. Each of the study participant’s current residential address was geocoded with the ArcGIS StreetMap data. Finally, GIS-selenium concentration was calculated by extracting the estimated selenium value from the IDW surface at each resident’s location. The inter-rater reliability of our GIS approach to calculating our groundwater elements is very high (Pearson Correlation coefficient > 0.9). In our prior work, we have found our GIS-based estimates to be very similar to concentrations found from direct measurement [35].

Polymerase chain reactions (PCRs) were utilized to genotype the GPX1 (rs1050450) polymorphism. Primers were purchased from Integrated DNA Technologies, Inc.: FW 5’-CTACGCAGGTACAGC-CGCCGCT-3’ and RV 5’-AAGGTGTCCCTCCCTCG-TAGGT-3’. Amplification conditions included: 100ng template DNA, DMSO, water, and GoTaq Green Master Mix (3mM MgCl2, 1X PCR buffer, 400 μM each dNTP). The amplicons of the GPX1 gene were digested with the restriction enzyme ApaI with 0.18 μL per sample, 0.05 μL BSA, and 1 μL 10x buffer 4, leaving fragment sizes determined by the genotype of the studied individuals (pro/pro = 191 bp; pro/leu = 191, 117, and 74 bp; leu/leu = 117 and 74 bp). Digested fragments were separated on 1% agarose and visualized by ethidium bromide staining.

In order to examine the link between groundwater selenium exposures and affective status, linear regression models were created with SPSS version 18 using GDS-30 (total and subfactor) scores as outcome variables and selenium concentration as the predictor variables. Covariates entered into the models were age, gender, education, and language of administration. In order to obtain magnitude of relations, the amount of variance accounted for by selenium concentrations alone is also presented. Logistic regression models were created to determine the risk of depression, defined as GDS score ≥ 10, that were associated with (a) groundwater selenium concentrations and (b) the GPX1 Pro198Leu polymorphism.

**Results**

The mean age and education of the sample was 61.49 (sd = 12.70; range = 40-96) and 10.76 (sd = 4.37; range = 0-20), respectively. Mean GIS-based selenium concentration was 17.70 μg/L (sd = 10.66; range = 3.96-56.32). Seventy-seven percent of the sample was interviewed in English and 33% in Spanish; 88% of the sample self-reported their race as White, and 38% reported their ethnicity as Mexican American. Mean GDS-30 score of the sample was 10.49 (sd = 5.07; range = 0-26). Demographic characteristics of the sample are presented in Table 1.

Selenium concentrations were found to be significantly and negatively related to all GDS scores. Specifically, higher selenium levels were significantly related to lower scores in the Total GDS-30 scores (β = -0.34, p < 0.001), explaining 11% of the variance. Higher selenium was also related to a decrease in factor scores of Dysphoria (β = -0.23, p < 0.001), explaining 5% of the variance, Meaninglessness (β = -0.42, p < 0.001), explaining 17% of the variance, and Apathy (β = -0.30, p < 0.001), explaining 9% of the variance. Higher selenium concentration was statistically a significant predictor of lower scores on the subfactor of Cognitive Impairment (β = -0.11, p = 0.01), but only accounted for 1% of the variance. The results of the regression analysis can be found in Table 2. Higher selenium concentration was also associated with a

| Table 1 Demographic characteristics | Mean (sd) | Range |
|-------------------------------------|-----------|-------|
| Age                                 | 61.45 (12.70) | 40-96 |
| Education                           | 10.76 (4.37) | 0-20  |
| GIS-selenium (μg/L)                 | 17.70 (10.67) | 3.96-56.32 |
| GDS Total                           | 10.49 (5.07) | 0-26  |
| GDS Dysphoria                       | 3.31 (2.44)  | 0-11  |
| GDS Meaninglessness                 | 2.24 (1.43)  | 0-7   |
| GDS Apathy                          | 2.87 (1.42)  | 0-6   |
| GDS Cognitive Impairment            | 1.87 (1.19)  | 0-6   |
| GPX1 Polymorphism (%)               |            |       |
| CC                                  | 46         |       |
| CT                                  | 48         |       |
| TT                                  | 6          |       |
significantly lower risk of depression, with $B = -0.06$ (SE = 0.01), Wald (df = 1) = 37.25, $p < 0.001$, and OR = 0.94 (95% CI = 0.92-0.96).

The link between depression and GPX1 polymorphisms was strongest for CC (homozygous wild type) and TT (homozygous mutant type) carriers, with the greatest impact being for TT individuals as shown in Table 3. The TT polymorphism was the least frequent in the sample; however, for TT individuals, selenium concentrations accounted for 26% of the variance in GDS Total Score, 13% of the variance in Dysphoria, 37% of the variance in Meaninglessness, and 19% of the variance in Apathy. For the CC polymorphism, selenium concentrations accounted for 15% of the variance in total score, 9% of the variance in Dysphoria, 22% of the variance in Meaninglessness, and 14% of the variance in Apathy. The amount of variance for CT polymorphism was relatively small.

Next, we examined the impact of the GPX1 Pro198Leu polymorphism on the findings. First, we sought to determine if homozygous carriage of the C allele was associated with depression status (GDS $\geq 10$ = depressed), compared to T allele carriers (CT plus TT; TT was not analyzed separately due to sample size). Logistic regression was conducted with depressed status as the outcome variable and GPX1 polymorphism (CC versus CT) as a categorical predictor variable. Sixty-six percent of CC homozygotes were depressed compared to 57% for T allele carriers; therefore, homozygous carriage of the C allele was associated with a significantly increased risk of depression ($B = 0.50$, SE = 0.19, Wald (df = 1) = 6.88, $p = 0.009$, and OR = 1.65 (95% CI = 1.14-2.40). Next, a linear regression model was created to examine the gene-dose effect of GPX1 C versus T (CC = 2, CT = 1, TT = 0) alleles on depression scores (GDS total score). With age, gender, education, and test language entered as covariates, the increasing presence of the T allele was associated with significantly higher GDS scores ($B = 0.94$, SE = 0.35, $t = 2.69$, and $p = 0.008$). Lastly, we re-ran our regression analyses examining the link between selenium concentrations and

| Table 2 Linear regression results | B (SE) | t score | p value | % Variance accounted For |
|---------------------------------|-------|--------|---------|--------------------------|
| GDS Total                       | -0.16 (0.02) | -8.21  | 0.000   | 11%                      |
| GDS Dysphoria                   | -0.05 (0.01)  | -5.24  | 0.000   | 5%                       |
| GDS Meaninglessness             | -0.06 (0.006) | -10.31 | 0.000   | 17%                      |
| GDS Apathy                      | -0.04 (0.006) | -7.11  | 0.000   | 9%                       |
| GDS Cognitive Impairment        | -0.13 (0.005) | -2.53  | 0.012   | 1%                       |

| Table 3 Linear Regression Results by GPX1 Allele | B (SE) | t score | p value | Model variance | Selenium variance |
|-----------------------------------------------|-------|--------|---------|----------------|-------------------|
| CC (n = 221)                                  |       |        |         |                |                   |
| GDS Total                                     | -0.18 (0.03) | -6.40  | <0.001  | 21%            | 15%               |
| GDS Dysphoria                                 | -0.05 (0.02)  | -3.24  | 0.001   | 9%             | 4%                |
| GDS Meaninglessness                           | -0.06 (0.007) | -8.04  | <0.000  | 24%            | 22%               |
| GDS Apathy                                    | -0.05 (0.008) | -6.10  | <0.000  | 18%            | 13%               |
| GDS Cognitive Impairment                      | -0.02 (0.007) | -2.96  | 0.003   | 7%             | 5%                |
| CT (n = 208)                                  |       |        |         |                |                   |
| GDS Total                                     | -0.13 (0.04) | -3.58  | <0.001  | 10%            | 6%                |
| GDS Dysphoria                                 | -0.05 (0.02)  | -2.99  | 0.003   | 9%             | 4%                |
| GDS Meaninglessness                           | -0.05 (0.01)  | -4.68  | <0.001  | 12%            | 9%                |
| GDS Apathy                                    | -0.03 (0.01)  | -2.74  | 0.007   | 3%             | 3%                |
| GDS Cognitive Impairment                      | 0.00 (0.008)   | -0.05  | 0.96    | 2%             | 0%                |
| TT (n = 33)                                   |       |        |         |                |                   |
| GDS Total                                     | -0.27 (0.07)  | -3.78  | <0.001  | 40%            | 26%               |
| GDS Dysphoria                                 | -0.08 (0.04)  | -2.27  | 0.03    | 21%            | 13%               |
| GDS Meaninglessness                           | -0.11 (0.2)    | -5.11  | <0.000  | 53%            | 37%               |
| GDS Apathy                                    | -0.06 (0.02)  | -2.81  | 0.009   | 28%            | 19%               |
| GDS Cognitive Impairment                      | -0.02 (0.3)    | -0.73  | 0.47    | 3%             | 2%                |
GDS scores (total and subfactors) after stratification of the sample on genotype at the GPX1 Pro198Leu polymorphism. The link between selenium levels and depression was strongest among CC and TT, as compared to CT individuals. The TT polymorphism was the least frequent in the sample. Of note, in regression analysis of groundwater selenium levels on depression risk, models that included Pro198Leu genotype along with age, gender, education, and language of test administration accounted for more variance (70%) than those that did not include genotypic status (50%). For CC polymorphism, selenium concentrations alone accounted for 15% of the variance in total score, 9% of the variance in dysphoria, 22% of the variance in meaninglessness, and 14% of the variance in apathy, which was more variance accounted for than found by covariates. The amount of variance for CT polymorphism was relatively small. See Table 3.

Therefore, these findings point to a gene-environment interaction, which is supported by the gene-dose findings.

Discussions and conclusions
In the past three decades, selenium has been found to be essential to various aspects of health [47]. It has been found to play a role in prevention of cancer and cardiovascular disease as well as in regulating mood [20]. Exposure to environmental factors, such as selenium, can also play a role in depression and anxiety states. Past research has shown that low selenium concentrations were related to depression status and other negative affective states [18,20]. In addition, studies have indicated that selenium may be useful in preventing postpartum depression [22].

In the current study, higher groundwater selenium levels were associated with lower scores on the Geriatric Depression Scale. This finding is consistent with past research indicating that low selenium status is related to increased incidence of depression and other negative affective states [18,20]. In addition to the decrease in total depression scores, higher selenium levels were specifically related to a decrease in symptoms of Dysphoria, Meaninglessness, and Apathy, indicating that selenium may have an impact on particular types of depressive manifestations. It is interesting to note that selenium concentrations were only minimally related to the cognitive impairment subscale, as we have previously shown selenium to be selectively protective of memory functioning [36]. This suggests that, despite the potential role of selenium concentrations in preserving cognitive function, depressive symptoms related to thoughts of cognitive dysfunction appear to be unrelated and may be related to the concept of insight.

This is the first study to examine residential groundwater selenium levels and depression. A myriad of factors determine the chemical make-up of groundwater in a given area, and it is important to be cognizant of the potential health impacts from such substances. Research on groundwater and its implications on human health can have profound implications in the realms of public health and policy. Additionally, results obtained by groundwater research could prove to be the impetus for the formation or reformation of population-based prevention strategies concerning groundwater safety and exposure. This study was conducted in a rural agricultural area where higher concentrations of groundwater selenium are typically found. Aligning with this, the mean selenium level in this study was 17.70 μg/L, whereas the national average is 10 μg/L [48].

The protective impact of selenium on mental health fits with its biological activity and is supported by both animal model and human research. Selenium, a main constituent of neuronal selenoproteins, may be particularly important for sustaining healthy cerebral function [47] through its key role in protection against oxidative damage [15,20,49]. Oxidative damage is a key biological mechanism in depression pathophysiology, and many anti-depressants, like fluoxetine [50] and venlafaxine [51], reduce oxidative damage. Another possible mechanism of action is through selenium's impact on brain-derived neurotrophic factor (BDNF), which has been linked to depression and found to be decreased in selenium deficient rats [52]. Additionally, depression is also associated with lower antioxidant levels. Research has suggested that antioxidant deficiency found in depression may predispose individuals to greater inflammatory and oxidative and nitrosative responses [13], which may contribute to the protective effects of selenium against depression.

Ours is the first study to directly examine the link between the GPX1 Pro198Leu polymorphism and depressive risk as well as its impact on the selenium-depression link. Our findings point to gene-environment interaction, which is supported by the gene-dose impact. Specifically, the C allele of the GPX1 polymorphism was associated with significantly increased risk of depression in a dose-dependent manner (i.e. CC > CT > TT). Additionally, the impact of environmental selenium concentrations on depression scores was stronger for the CC than CT group. The TT group showed a substantial impact in the expected direction, but due to the small sample number of TT homozygotes, these results must be replicated. It is also important to note the differences in effect sizes for selenium on depression observed in each genotypic group. Among CC homozygotes, the majority of variance accounted for in GDS scores was from selenium concentrations with age, gender, education, and language of test administration contributing less to GDS scores. Among the TT group, the amount of variance accounted for by selenium concentrations alone was substantial; however, covariates in the model also accounted for a larger portion of the variance. Future work is needed to delve more thoroughly into this
gene-environment interaction as well as the dose-response impact of the C allele of the GPX1 polymorphism on risk for depression. Additional work is also required to examine other potential genes of interest. For example, Galecki and colleagues [53] identified polymorphisms of the NOS2A gene, which are important in the nitric oxide pathways, as related to recurrent depression. Given that selenium (i.e. selenoproteins) is involved in the nitric oxide pathway as well, NOS2A and other genes relevant to pathways linked to selenium should be examined. It is likely that more sophisticated bioinformatic analyses will be necessary to disentangle these multi-level gene-(biological mechanism) – environmental exposure – depression interactions.

These results point towards possible pharmacogenetic implications of the Pro198Leu GPX1 polymorphism. Specifically, in our sample, CC homozygotes had significantly increased risk for depression; however, selenium was also most powerfully protective against depression and depressive symptoms among those particular carriers. Therefore, future research looking at the therapeutic impact of selenium on depression should examine this genotype. Additionally, previously conducted clinical trials of antidepressant medications with stored DNA (or previously conducted genetic analyses) can determine if Pro198Leu GPX1 genotype predicts optimal treatment response. Lastly, the Pro198Leu GPX1 polymorphism may be useful for identifying those individuals most likely to benefit from anti-depressant medications in new clinical trials.

There are limitations to the current study. One is the GIS-based estimate of selenium concentration rather than direct measurement. However, our prior work, as well as that of others, has shown that GIS-based methods are valid ways for estimating environmental exposures. The current findings should be replicated using direct selenium measurement. The cross-sectional nature of the study is another limitation; however, our prior work has shown selenium to be preventative of cognitive decline prospectively in a subset of this cohort [30]. Future studies will examine the protective impact of selenium concentrations on both depression and cognitive decline as future waves become available. The current study also has several strengths. Specifically, this is the first study to examine this link in such detail (i.e. depressive symptoms rather than only global scores) as well as look at this topic among rural-dwelling adults and elders. This is also the first study to examine the impact of genetic variation within GPX1 on depression risk as well as the selenium-depression link. Taken together, these results point to the need for continued work in the area, as selenium may provide a therapeutic target for preventative strategies aimed at reducing depressive incidence rates in vulnerable populations. Additional work is also needed to determine the pharmacogenetic implications of the Pro198Leu GPX1 polymorphism in depression therapies.

Abbreviations
CBPR: Community-based participatory research; GDS: Geriatric depression scale; GIS: Geospatial information system; GPX1: Glutathione peroxidase 1; SNP: Single nucleotide polymorphism; TWDB: Texas water development board; BDNF: Brain-derived neurotrophic factor; PCR: Polymerase chain reactions; CC: Homozygous wild type alleles; TT: Homozygous mutant type alleles.

Competing interests
The authors declare no competing financial interests. This work was funded in part by the Science To Achieve Results (STAR) Program of the U.S. Environmental Protection Agency (EPA) grant # RD83479401 (O’Bryant, PI), National Institute on Minority Health and Health Disparities (NMHD) award #L60MD001849 and the Hogg Foundation grant # JRG-040 (O’Bryant, PI).

Authors’ contributions
Li: Designed the study, participated in data collection and analysis, and manuscript preparation. JP: Participated in data collection, entry, and manuscript preparation. CM: Participated in data collection and manuscript preparation. ME: Participated in data collection and analysis, and manuscript preparation. JH: Assisted in study design, data analysis, and manuscript preparation. RB: Assisted in study design, data analysis, and manuscript preparation. TC: Assisted in data analysis, and manuscript preparation. EH: Participated in manuscript preparation. SO: Designed the study, participated in data collection and analyses, and manuscript preparation. All authors have read and approved this manuscript.

Acknowledgements
This work was funded in part by the Science To Achieve Results (STAR) Program of the U.S. Environmental Protection Agency (EPA) grant # RD83479401 (O’Bryant, PI), and the Hogg Foundation grant # JRG-040 (O’Bryant, PI). We would like to thank all of the participants of Project FRONTER along with the incredible support staff that make this study possible.

Author details
1Department of Internal Medicine, Institute for Aging & Alzheimer’s Disease Research, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA. 1Department of Psychology, University of North Texas, Denton, TX, USA. 2Department of Internal Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA. 3Department of Psychiatry, University of North Texas Health Science Center, Fort Worth, TX, USA. 4Department of Pharmacology & Neuroscience, Institute for Aging & Alzheimer’s Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA. 5Department of Internal Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA. 6Department of Internal Medicine, Institute for Aging & Alzheimer’s Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA. 7Department of Internal Medicine, Institute for Aging & Alzheimer’s Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA. 8Texas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA. 9Department of Internal Medicine, Institute for Aging & Alzheimer’s Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA. 10Texas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA. 11Department of Internal Medicine, Institute for Aging & Alzheimer’s Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA. 12Department of Internal Medicine, Institute for Aging & Alzheimer’s Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA. 13Department of Internal Medicine, Institute for Aging & Alzheimer’s Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA.

Received: 27 July 2012 Accepted: 19 December 2012
Published: 4 January 2013

References
1. Diabetes surveillance. 1999, 2000, 2000. www.cdc.gov/diabetes/statistics. surv1999/June 2002.
2. CDC: Current depression among adults - united states, 2006 and 2008. MMWR 2010, 59(38):1229–1235.
3. Gosney MA, Hammond MF, Shenkin A, Allsup S: Effect of micronutrient supplementation on mood in nursing home residents. Gerontology 2008, 54(5):292–299.
4. Arnold B, Montgomery G, Castaneda L, Longoria R: Acculturation and performance of Hispanics on selected halstead-reitan neuropsychological tests. Assessment 1994, 1:239–248.
5. Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC: Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000, 15(6):319–328.
6. Beekman ATF: The association of physical health and depressive symptoms in the older population: Age and sex differences. Soc Psychiatry Psychiatr Epidemiol 1995, 30(1):32–38.
7. Geerlings SW, Beekman AT, Deeg D, van Tilburg W: Physical health and the onset and persistence of depression in older adults: an eight-wave prospective community-based study. Psychol Med 2000, 30(3):369–380.
8. Watson GS, Craft S: The role of insulin resistance in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs 2003, 17(1):27–45.
9. Saadat M, Zendeh-Boodi Z, Ali Goodarzi M: Environmental exposure to natural sour gas containing sulfur compounds results in elevated depression and hopelessness scores. Environ Toxicol Saf 2006, 65(2):288–291.
10. Beseler C, Stallones L, Hoppin J, Alavanja MCR, Blair A, Keefe T, Kamel F: Depression and pesticide exposures in female spouses of licensed pesticide applicators in the agricultural health study cohort. J Occup Environ Med 2006, 48(10):1005–1013.
11. Van Cauwenbergh RV, Robberecht H, Vaeslaer V: A comparison of the serum selenium content of healthy adults living in the Antwerp region (Belgium) with recent literature data. J Trace Elem Med Biol 2004, 18:99–112.
12. Maes M, Yirmiya R, Noraberg J, Breen S, Hibblel J, Perini G, Kubera M, Bob P, Lerer B, Maj M: The inflammatory & neurodegenerative (INiND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009, 24(1):27–53.
13. Maes M, Galecki P, Chang YS, Berk M: A review on the oxidative and nitrosative stress (ONOS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):676–692.
14. Ozdemir E: Physiopathological role of selenium and selenoprotein in neuropsychiatric disease. J Med Sci 2011, 11(1):11–18.
15. Mostert V: Selenoprotein P: properties, functions, and regulation. Arch Biochem Biophys 2000, 376(2):433–438.
16. Kodydková J, Vávrová L, Zeman M, Jirák R, Macásek J, Stanková B, Tvrzická E, Zák A: Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem 2009, 42(13–14):1368–1374.
17. Ozcan ME, Gulec M, Ozeri E, Pokat, R, Akyol D: Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004, 19(2):289–295.
18. Hawkes WC, Hornbostel L: Effects of dietary selenium on mood in healthy men living in a metabolic research unit. Biol Psychiatry 1996, 39(2):121–128.
19. Papp LV, Holmgren A, Khanna KK: Selenium and selenoproteins in health and disease. Antioxid Redox Signal 2010, 12(7):795–799.
20. Rayman MP: The importance of selenium to human health. Lancet 2000, 356(9225):233–241.
21. Rayman MP, Thompson A, Warren-Perry M, Galassini R, Catterick J, Hall E, Mobarhan M, Sahebkar A, Majdi MR, Tavallaie S, Azimi-Nezhad M, et al: Effect of supplementation with selenium on postpartum depression: a randomized double-blind placebo-controlled trial. J Matern Fetal Neonatal Med 2011, 24(1):104–108.
22. Pasco JA, Jacka FN, Williams LJ, Evans-Cleaver M, Brennan SL, Kotowicz MA, Nicholson GC, Boll MJ, Berk M: Dietary selenium and major depression: a nested case- control study. Complement Ther Med 2012, 20(3):119–123.
23. Gao S, Jin Y, Unverzagt F, Liang C, Hall K, Cao J, Ma F, Murrell J, Cheng X, Li P, et al: Selenium level and depressive symptoms in a rural elderly Chinese cohort. BMC Psychiatry 2012, 12(1):72.
24. Maes M, Mihaylova J, Kubera M, Utterhoffen M, Vrydaghs N, Bosmans E: Lower whole blood glutathione peroxidase (GPx) activity in depression, but not in myalgic encephalomyelitis / chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression. Neuroendocrinol Lett 2011, 32(2):133–140.
25. Soeren sen M, Christensen K, Steen garve T, Christiansen L: The Mn-superoxide dismutase single nucleotide polymorphism rs4880 and the glutathione peroxidase 1 single nucleotide polymorphism rs1050450 are associated with aging and longevity in the oldest old. Mech Ageing Dev 2009, 130(5):308–314.
26. Ravn-Haren G, Olsen A, Tjenneland A, Dragsted LO, Nexø BA, Wallin H, Overvad K, Raischou-Nielsen O, Vogel U: Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPx activity, alcohol consumption and breast cancer risk in a prospective cohort study. Carcinogenesis 2006, 27(4):820–825.
27. Pera J, Slowik A, Dziedic T, Pulyk R, Wloch D, Szczudlik A: Glutathione peroxidase 1 C593T polymorphism is associated with lobar intracerebral hemorrhage. Cerebrovasc Dis 2008, 25(5):445–449.
28. Coffey DM, Marmol L, Schock L, Adams W: The influence of acculturation on the Wisconsin card sorting test by Mexican Americans. Arch Clin Neuropsychol 2005, 20(6):795–803.
29. Tang NP, Wang LS, Yang L, Gu HJ, Sun QM, Cong RH, Zhou B, Zhu HJ: Reliant artery disease in a Chinese population. Clin Chim Acta 2008, 395(1–2):89–93.
30. U.S. Interim projections by Age, Sex, and Hispanic origin. http://www.census.gov/ipc/www/usinterproj/.
31. Chen J, Cao Q, Qin C, Shao P, Wu Y, Wang M, Zhang Z, Yin C: GPX1 polymorphism (rs1050450) contributes to tumor susceptibility: evidence from meta-analysis. J Cancer Res Clin Oncol 2011, 137(10):1553–1561.
32. Cominiatti C, de Bortoli MC, Purgato E, Ong TP, Moreno FS, Gаридо AR, Cozzolino SM: Associations between glutathione peroxidase-1 Pro198Leu polymorphism, selenium status, and DNA damage levels in obese women after consumption of brazil nuts. Nutrition 2011, 27(9):891–896.
33. O’Fallon LR, Deary A: Commitment of the national institute of environmental health sciences to community-based participatory research for rural health. Environ Health Perspect 2001, 109:469–473.
34. O’Byrant S, Edwards M, Menon CV, Gong G, Barber R: Long-term low-level arsenic exposure is associated with poorer neuropsychological functioning: a project FRONTIER study. Int J Environ Res Public Health 2011, 8(8):874–879.
35. Hall J, Edwards M, Barber RC, Johnson LA, Gong G, O’Byrant SE: Higher groundwater selenium exposure is associated with better memory: a project FRONTIER study. Neurosci Med 2012, 3(1):8–25.
36. Johnson LA, Hobson V, Jenkins M, Denti na A, Ragain M, O’Byrant S: The influence of thyroid function on cognition in a sample of ethnically diverse, rural-dwelling women: a project frontier study. J Neuropsychiatr Clin Neurosci 2011, 23(2):219–222.
37. Yesavage JA, Brink TL, Rose TL, et al: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982, 17:509–515.
38. Mui AC: Geriatric depression scale as a community screening instrument for elderly Chinese immigrants. Int Psychogeriatr 1996, 8(3):445–458.
39. Hall J, Davis TE: Factor structure of the geriatric depression scale in cognitive impaired older adults. Clin Gerontol 2010, 33:39–48.
40. Gong G, O’Byrant SE: The arsenic exposure hypothesis for Alzheimer’s disease. Alzheimer Dis Assoc Disord 2010, 24(4):311–316.
41. Avuskina GA, Jacquest GM, Melliker JR, Slatonick MJ, Kaufmann AM, Ninagau JO: Visualization and exploratory analysis of epidemiologic data using a novel space time information system. Int J Health Geogr 2004, 3:art. no. 26.
42. Su CC, Lin YY, Chang TK, Chang CT, Chung JA, Hsu YC, Lian IB: Incidence of oral cancer in relation to nickel and arsenic concentrations in farm soils of patients’ residential areas in Taiwan. BMC Publ Health 2010, 10: art. no. 67.
43. Khan NJ, Owens G, Bruce D, Naidu R: Human arsenic exposure and risk assessment at the landscape level: a review. Environ Geochim Heal 2009, 31(SUPPL. 1):143–166.
44. Samadder SR, Subbarao C: GIS approach of delineation and risk assessment of areas affected by arsenic pollution in drinking water. J Environ Eng 2007, 133(7):742–749.
45. Gong G, Hargrave KA, Hobson V, Spallholz J, Boylan M, Lefforge D, O’Byrant SE: Low-level groundwater arsenic exposure impacts cognition: a project FRONTIER study. J Environ Health 2013, 74(26):16–22.
46. Chen J, Berry MJ: Selenium and selenoproteins in the brain and brain diseases. J Neurochem 2003, 86(1):1–12.
47. Barceloux DG: Selenium. J Toxicol Clin Toxicol 1999, 37(2):145–172.
48. Schwebler U, Bräuer AU, Köhlle J, Nitsch R, Savaskan NE: Selenium and brain function: a poorly recognized liaison. Brain Res Rev 2004, 45(4):164–178.
50. Moretti M, Colla A, de Oliveira Balen G, dos Santos DB, Budni J, Freitas AE, Farina M, Rodrigues AL: Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress. J Psychiatr Res 2012, 46(3):331–340.

51. Abdel-Wahab BA, Salama RH: Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice. Pharmacol Biochem Behav 2011, 100(1):59–65.

52. Green A, Garrick T, Sheedy D, Blake H, Shores A, Harper C: Repeatable battery for the assessment of neuropsychological status (RBANS): preliminary Australian normative data. Aust J Psychol 2008, 60(2):72–79.

53. Galecki P, Maes M, Florkowski A, Lewinski A, Galecka E, Bierkiewicz M, Szemraj J: Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder. J Affect Disord 2011, 129(1–3):175–182.

doi:10.1186/1471-244X-13-7

Cite this article as: Johnson et al.: The impact of GPX1 on the association of groundwater selenium and depression: a project FRONTIER study. BMC Psychiatry 2013 13:7.